These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36872371)

  • 1. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
    Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
    J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
    Saad MB; Hong L; Aminu M; Vokes NI; Chen P; Salehjahromi M; Qin K; Sujit SJ; Lu X; Young E; Al-Tashi Q; Qureshi R; Wu CC; Carter BW; Lin SH; Lee PP; Gandhi S; Chang JY; Li R; Gensheimer MF; Wakelee HA; Neal JW; Lee HS; Cheng C; Velcheti V; Lou Y; Petranovic M; Rinsurongkawong W; Le X; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Antonoff MB; Sepesi B; Lewis J; Wistuba II; Hazle JD; Chung C; Jaffray D; Gibbons DL; Vaporciyan A; Lee JJ; Heymach JV; Zhang J; Wu J
    Lancet Digit Health; 2023 Jul; 5(7):e404-e420. PubMed ID: 37268451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 7. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
    Park KJ; Lee JL; Yoon SK; Heo C; Park BW; Kim JK
    Eur Radiol; 2020 Oct; 30(10):5392-5403. PubMed ID: 32394281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
    Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
    Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
    J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
    Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
    J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 13. CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer.
    Xu T; Liu X; Chen Y; Wang S; Jiang C; Gong J
    BMC Med Imaging; 2024 Jul; 24(1):196. PubMed ID: 39085788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
    Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
    J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients.
    Caii W; Wu X; Guo K; Chen Y; Shi Y; Chen J
    Cancer Immunol Immunother; 2024 Jun; 73(8):153. PubMed ID: 38833187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics of
    Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.
    Yang Y; Yang J; Shen L; Chen J; Xia L; Ni B; Ge L; Wang Y; Lu S
    Am J Transl Res; 2021; 13(2):743-756. PubMed ID: 33594323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of computed tomography radiomics combined with inflammation indices in predicting the efficacy of immunotherapy in patients with locally advanced and metastatic non-small cell lung cancer.
    Shao H; Zhu J; Shi L; Yao J; Wang Y; Ma C; Swierniak A; Ni B
    J Thorac Dis; 2024 May; 16(5):3213-3227. PubMed ID: 38883654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.